Shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) saw an uptick in trading volume on Wednesday . 167,959 shares traded hands during mid-day trading, an increase of 17% from the previous session’s volume of 143,899 shares.The stock last traded at $9.00 and had previously closed at $9.32.

AQXP has been the topic of several research analyst reports. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Wednesday. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Needham & Company LLC initiated coverage on Aquinox Pharmaceuticals in a research note on Thursday, May 12th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, Jefferies Group raised their price objective on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Aquinox Pharmaceuticals has an average rating of “Buy” and an average price target of $19.86.

The stock’s 50 day moving average is $8.09 and its 200-day moving average is $8.46. The stock’s market cap is $154.91 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.22. On average, analysts forecast that Aquinox Pharmaceuticals Inc. will post ($2.11) earnings per share for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.